NXTC
NASDAQ HealthcareNextCure, Inc. - Common Stock
Biotechnology
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
๐ Market Data
| Price | $7.71 |
|---|---|
| Volume | 183,347 |
| Market Cap | 35.29M |
| Beta | 1.270 |
| RSI (14-Day) | 65.7 |
| 200-Day MA | $9.35 |
| 50-Day MA | $3.93 |
| 52-Week High | $15.74 |
| 52-Week Low | $1.55 |
| Forward P/E | -1.34 |
| Price / Book | 0.77 |
๐ฏ Investment Strategy Scores
NXTC scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (72/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (18/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NXTC in your text
Paste any article, transcript, or post โ the tool will extract NXTC and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.